Solasia Pharma
Stage
IPO | IPOTotal Raised
$7.8MDate of IPO
3/23/2017About Solasia Pharma
Solasia Pharma, formerly known as JapanBridge, expedites patient access to unique oncology therapies through aggressive development and specialized commercialization throughout Japan, China and other Asian countries. Solasia has Asian rights to Sancuso (extended release granisetron transdermal patch) from ProStrakan Group plc and an exclusive license to ZIOPHARM's SP-02 / darinaparsin, in major Asian countries. Solasia is currently conducting a Phase 1 study of darinaparsin in PTCL in Japan and Korea.
Missing: Solasia Pharma's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Solasia Pharma's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Solasia Pharma
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Solasia Pharma is included in 2 Expert Collections, including Cancer.
Cancer
1,179 items
Pharmaceutical and biotechnology companies with cancer therapy drug candidates.
Biopharma Tech
15,535 items
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Solasia Pharma Patents
Solasia Pharma has filed 5 patents.
The 3 most popular patent topics include:
- Antineoplastic drugs
- Experimental cancer drugs
- Monoclonal antibodies
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
10/15/2020 | 5/10/2022 | Experimental cancer drugs, Transcription factors, Oncology, Antineoplastic drugs, Monoclonal antibodies | Grant |
Application Date | 10/15/2020 |
|---|---|
Grant Date | 5/10/2022 |
Title | |
Related Topics | Experimental cancer drugs, Transcription factors, Oncology, Antineoplastic drugs, Monoclonal antibodies |
Status | Grant |
Latest Solasia Pharma News
Aug 22, 2022
August 22, 2022 06:30 AM Eastern Daylight Time TOKYO--( BUSINESS WIRE )--Solasia Pharma K.K. (TOKYO:4597, Headquarters: Tokyo, Japan, President & CEO: Yoshihiro Arai, hereinafter “Solasia”) officially announced today that an organoarsenic drug “DARVIAS® Injection 135mg” (SP-02, hereinafter DARVIAS®) has been launched today in Japan for use in relapsed or refractory Peripheral T-Cell Lymphoma. DARVIAS® will be commercialized by Nippon Kayaku Co., Ltd. (TOKYO:4272, Headquarters: Tokyo, Japan, President: Atsuhiro Wakumoto). Contacts
Solasia Pharma Frequently Asked Questions (FAQ)
Where is Solasia Pharma's headquarters?
Solasia Pharma's headquarters is located at 3F, Shiodome Building, Tokyo.
What is Solasia Pharma's latest funding round?
Solasia Pharma's latest funding round is IPO.
How much did Solasia Pharma raise?
Solasia Pharma raised a total of $7.8M.
Who are the investors of Solasia Pharma?
Investors of Solasia Pharma include ITOCHU, MPM Capital and Kyowa Kirin.
Who are Solasia Pharma's competitors?
Competitors of Solasia Pharma include Ology Bioservices, Adastra Pharmaceuticals, Salix Pharmaceuticals, ANI Pharmaceuticals, Supernus Pharmaceuticals and 11 more.
Compare Solasia Pharma to Competitors
Alinea Pharmaceuticals, Inc. offers pharmaceuticals for diabetes and related metabolic disorders
Ausio Pharmaceuticals is a company focused on the clinical development of S-Equol for major medical needs.
Bluefish Pharmaceuticals offers a range of quality pharmaceuticals at prices that as many as possible will be able to afford.
Greystone Pharmaceuticals is a healthcare company focused on wound technologies.
Arriva Pharmaceuticals, Inc. offers enzyme inhibitor replacement & therapy
Zebra Pharmaceuticals offers customized health products through nature and science.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.